Pfizer Researcher Says miRNA Markers Have Promise Beyond Oncology, but a Lengthy Development Runway | GenomeWeb

By Doug Macron

Though microRNAs hold great promise as diagnostic and prognostic biomarkers for a variety of complex diseases, their development for these applications outside of cancer remains years away, a Pfizer researcher said this week.

Indeed, cancer researchers have been a major force driving clinical applications of miRNAs, with at least four diagnostics based on the non-coding RNAs already commercialized.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.